Overview

Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

To investigate safety and efficacy of single agent sunitinib malate as first-line systemic therapy in Chinese patients with metastatic renal cell carcinoma.

Phase:

Phase 4

Details

Lead Sponsor:

Pfizer

Treatments:

Sunitinib